RJFSA
DYN icon

Raymond James Financial Services Advisors’s Dyne Therapeutics DYN Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.39M Sell
38,782
-6
-0% -$239 ﹤0.01% 1940
2024
Q2 		$1.37M Buy
38,788
+7,884
+26% +$229K ﹤0.01% 1893
2024
Q1 		$877K Buy
+30,904
New +$699K ﹤0.01% 2145

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Raymond James Financial Services Advisors's DYN Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Dyne Therapeutics (DYN) stake by 0.02% in Q3 2024, selling an estimated $239 and leaving 38,782 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #1940.

Raymond James Financial Services Advisors first reported a position in DYN in Q1 2024 and has held it in 3 quarters since. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • Raymond James Financial Services Advisors held 38,782 shares of Dyne Therapeutics worth $1.39M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 6 Dyne Therapeutics shares in Q3 2024, an estimated $239.
  • Dyne Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1940 holding.
  • Raymond James Financial Services Advisors first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.